Business Segments · Unrealized gain (loss) on equity investments
Business Segments — Unrealized gain (loss) on equity investments
Neurocrine Biosciences Business Segments — Unrealized gain (loss) on equity investments decreased by 17.3% to $25.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 182.7%, from -$30.60M to $25.30M. Over 2 years (FY 2022 to FY 2024), Business Segments — Unrealized gain (loss) on equity investments shows a downward trend with a 9.8% CAGR.
Analysis
StatementSegment
CategoryOther
SignalContext dependent
VolatilityVolatile
First reportedQ1 2022
Last reportedQ1 2026May 5, 2026
Rolls up toUnrealized Gain (Loss) on Equity Securities
How to read this metric
Fluctuations reflect broader market volatility and the performance of the companies in which the firm has invested.
Detailed definition
Captures the change in market value of the company's minority equity holdings in other entities. This reflects the perfo...
Peer comparison
Common for companies with venture-style investment arms; often excluded from non-GAAP operating metrics.
Metric ID:
nbix_segment_reportable_segment_unrealized_gain_loss_on_equity_investmentsHistorical Data
16 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.70M | $7.70M | $7.70M | $7.70M | $7.10M | $7.10M | $7.10M | $7.10M | $1.60M | -$19.90M | -$16.90M | -$1.90M | -$30.60M | -$6.70M | $30.60M | $25.30M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -7.8% | +0.0% | +0.0% | +0.0% | -77.5% | <-999% | +15.1% | +88.8% | <-999% | +78.1% | +556.7% | -17.3% |
| YoY Change | — | — | — | — | -7.8% | -7.8% | -7.8% | -7.8% | -77.5% | -380.3% | -338.0% | -126.8% | <-999% | +66.3% | +281.1% | +182.7% |
Range-$30.60M – $30.60M
CAGR+37.3%
Avg YoY Growth-203.0%
Median YoY Growth-7.8%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's business segments — unrealized gain (loss) on equity investments?
- Neurocrine Biosciences (NBIX) reported business segments — unrealized gain (loss) on equity investments of $25.30M in Q1 2026.
- How has Neurocrine Biosciences's business segments — unrealized gain (loss) on equity investments changed year-over-year?
- Neurocrine Biosciences's business segments — unrealized gain (loss) on equity investments increased by 182.7% year-over-year, from -$30.60M to $25.30M.
- What is the long-term trend for Neurocrine Biosciences's business segments — unrealized gain (loss) on equity investments?
- Over 2 years (2022 to 2024), Neurocrine Biosciences's business segments — unrealized gain (loss) on equity investments has grown at a 9.8% compound annual growth rate (CAGR), from $30.80M to -$37.10M.
- What does business segments — unrealized gain (loss) on equity investments mean?
- The change in value of the company's stock investments that have not yet been sold.